Last reviewed · How we verify

Renal Cell Carcinoma — Treatment Landscape & Competitive Intelligence

Renal Cell Carcinoma (Oncology) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Oncology 10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Renal Cell Carcinoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Bavencio avelumab Merck KGaA Programmed Death Ligand-1 Blocker [EPC] Programmed cell death 1 ligand 1 2017-01-01
Lenvima LENVATINIB Eisai Kinase Inhibitor [EPC] Proto-oncogene tyrosine-protein kinase receptor Ret 2015-01-01
Inlyta axitinib Pfizer Kinase Inhibitor [EPC] Mast/stem cell growth factor receptor Kit 2012-01-01
Cometriq Cabometyx Exelixis Kinase Inhibitor Vascular endothelial growth factor receptor 2 2012-01-01
Cometriq CABOZANTINIB Exelixis Inc Kinase Inhibitor Vascular endothelial growth factor receptor 2 2012-01-01
Afinitor everolimus Novartis Kinase Inhibitor [EPC] Serine/threonine-protein kinase mTOR 2009-01-01
Torisel temsirolimus Pfizer Kinase Inhibitor Serine/threonine-protein kinase mTOR 2007-01-01
Sutent Sunitinib Malate Pfizer Small molecule kinase inhibitor Receptor tyrosine kinases (RTKs): PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, RET 2006-01-01
Sutent sunitinib Pfizer Moderate Risk QT Prolonging Agents 3-phosphoinositide-dependent protein kinase 1 2006-01-01
Sunitinib Malate sunitinib-malate Pfizer Moderate Risk QT Prolonging Agents 3-phosphoinositide-dependent protein kinase 1 2006-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 8 drugs in Renal Cell Carcinoma
  2. Bristol-Myers Squibb · 2 drugs in Renal Cell Carcinoma
  3. Central European Society for Anticancer Drug Research · 1 drug in Renal Cell Carcinoma
  4. Eisai · 1 drug in Renal Cell Carcinoma
  5. Exelixis · 1 drug in Renal Cell Carcinoma
  6. Exelixis Inc · 1 drug in Renal Cell Carcinoma
  7. Fujian Medical University · 1 drug in Renal Cell Carcinoma
  8. Institut National de la Santé Et de la Recherche Médicale, France · 1 drug in Renal Cell Carcinoma
  9. Merck KGaA · 1 drug in Renal Cell Carcinoma
  10. Novartis · 1 drug in Renal Cell Carcinoma
  11. Tracon Pharmaceuticals Inc. · 1 drug in Renal Cell Carcinoma
  12. Bausch Health · 1 drug in Renal Cell Carcinoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Renal Cell Carcinoma:

Cite this brief

Drug Landscape (2026). Renal Cell Carcinoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/renal-cell-carcinoma. Accessed 2026-05-17.

Related